| 摘要 |
An inhibitor for restenosis after percutaneous coronary arterioplasty (PTCA) which comprises, as an active ingredient, a compound of the following formula (1), (1') or a pharmaceutically acceptable salt thereof: (see formulas) wherein R1 and R2 are independently a hydrogen atom, a halogen atom, a trifluoromethyl group, a nitro group, a C1- C6 alkyl group or a C1-C6 alkoxyl group, and R1 and R2 may be linked to form a methylenedioxy group; R3 is an optionally substituted aryl group, an optionally substituted aromatic heterocyclic group, an optionally substituted 5 to 7-membered cycloalkyl or cycloalkenyl group; R4 is a hydrogen atom, a hydroxyl group, an -S-glutathione residue, an -S- a -amino acid residue, or an aralkyl group optionally having substituent(s) in the aryl moiety; R5 is a hydrogen atom or a C1-C6 alkyl group, and R4 and R5 may be linked to form a single bonds Y is an oxygen atom or a sulfur atom; n is an integer of from 0 to 5, and the selenium atom may be oxidized. The inhibitor of the present invention exhibits excellent inhibitory effect against restenosis after PTCA with low toxicity
|
